ClinicalTrials.gg

Program

rinatabart sesutecan

Its studies are mostly in Ovarian Neoplasms · Fallopian Tube Neoplasms · Endometrial Neoplasms · Gastrointestinal Neoplasms · Carcinoma, Non-Small-Cell Lung, led by Genmab.

Furthest: phase 3, since Sep 20, 20249 company-led studies, 9 open or runningNext primary completion: Sep 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genmab99 open or runningphase 3since Sep 20, 2024Oct 4, 2022Sep 2027phase 3 · NCT07604766

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 4, 2022First study: phase 2 study in Fallopian Tube NeoplasmsFirst studyNCT05579366 · 952 planned · United States, China, Japan and more
  2. Sep 20, 2024Phase 3 study in Ovarian NeoplasmsNCT06619236 · 584 enrolled · United States, Australia, Austria and more
  3. Sep 9, 2025Phase 3 study in Endometrial NeoplasmsNCT07166094 · 660 planned · United States, Australia, Belgium and more
  4. Nov 4, 2025Phase 3 study in Ovarian NeoplasmsNCT07225270 · 544 planned · United States, Australia, Austria and more
  5. Dec 15, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07288177 · 240 planned · United States, Australia, Belgium and more
  6. Apr 13, 2026Phase 2 study in Gastrointestinal NeoplasmsNCT07539311 · 160 planned · United States, Australia, Belgium and more
  7. Apr 27, 2026Phase 3 study in Ovarian NeoplasmsNCT07564141 · 688 planned · United States, Finland, Japan
  8. May 18, 2026Phase 3 study in Ovarian NeoplasmsNCT07604766 · 82 planned · China
  9. Sep 29, 2026Phase 3 study in Ovarian NeoplasmsNCT07859215 · 602 planned
  10. Nov 4, 2026Primary completion moved from 2027-07 to 2028-12Date moved laterphase 2 · +17 months · NCT05579366

Ahead

  1. Sep 2027Primary completion: phase 3 study in Ovarian NeoplasmsNCT07604766
  2. Nov 22, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07288177
  3. Sep 2028Primary completion: phase 2 study in Gastrointestinal NeoplasmsNCT07539311
  4. Oct 2028Primary completion: phase 3 study in Ovarian NeoplasmsNCT07225270

TargetBeta

FOLR1 →read by rule
“An antibody-drug conjugate (ADC) composed of a human monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) ”NCIt, by rule

Other programs on FOLR1

ProgramCompanyFurthest phaseStudies
mirvetuximab soravtansineruleAbbViephase 315
torvutatug samrotecanAstraZenecaphase 35
sofetabart mipitecanEli Lillyphase 32
opugotamig olatansineAbbViephase 22
Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901AbbViephase 11
Anti-FRa/Anti-CD3 Bispecific TCE NTB-928ruleteneoseven-incphase 11

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07859215Ovarian Neoplasms3Not yet recruitingMar 2030602
NCT07604766Ovarian Neoplasms · China3RecruitingSep 202782
NCT07564141Ovarian Neoplasms · United States, Finland, Japan3RecruitingDec 2029688
NCT07539311Gastrointestinal Neoplasms · United States, Australia, Belgium and more2RecruitingSep 2028160
NCT07288177Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more2RecruitingNov 22, 2027240
NCT07225270Ovarian Neoplasms · United States, Australia, Austria and more3RecruitingOct 2028544
NCT07166094Endometrial Neoplasms · United States, Australia, Belgium and more3RecruitingAug 2029660
NCT06619236Ovarian Neoplasms · United States, Australia, Austria and more3Active, not recruitingAug 18, 2026584
NCT05579366Fallopian Tube Neoplasms · United States, China, Japan and more2RecruitingDec 2028952

How it is read

Names in the registry

  • “Rina-S”, 9 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.